Advances in disease biology and pathophysiology
AL amyloidosis
CAR T cell sand other cellular therapies
Guidelines in specific clinical situations
Immunotherapy / Bispecific antibodies, Antibody drug conjugates, etc.
Minimal residual disease and disease assessment
Ongoing clinical trials and future trials
Options for refractory myeloma – sequencing of therapy in refractory disease
Outcome prediction and risk assessment
Smoldering myeloma, MGUS and precursor conditions
Therapy for non-transplant eligible patients
Treatment guidelines for young and fit patients
Small molecules and preliminary data
Waldenstrom macroglobulinemia
